Bioequivalence Study of Zidovudine 300 mg Tablets, USP Under Fed Conditions
Status:
Completed
Trial end date:
2005-04-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to assess the single-dose relative bioavailability of Ranbaxy
and GlaxoSmithKline (Retrovir ®) 300 mg Zidovudine tablets, under fed conditions